International Companies

Merck shares plunge on failure of cancer drug trial

By Josh White

Date: Tuesday 25 Jun 2024

(Sharecast News) - Shares of German chemical and pharmaceutical firm Merck were falling sharply on Tuesday, after it announced that a trial for its head and neck cancer drug xevinapant had been halted due to a lack of efficacy.
The development was the latest in a series of significant setbacks for...

Sign up for free or to read the full story

Email this article to a friend

or share it with one of these popular networks:


Article Archive

Top of Page